CD19 and acute lymphoblastic leukemia: In this regard, Gu and colleagues used the anti-CD19 scFv HI19α for the generation of a CD19-redirected CAR-T cell product, named CNCT19, which was later investigated in a clinical trial (NCT02975687) for the treatment of twenty individuals with R/R B-ALL [62].